1) Patient or legal representative refusal 2) Receiving palliative care with no active treatment 3) Known veno-occlusive disease 4) Chronic Obstructive Pulmonary Disease (known FEV1 < 50% predicted or ambulatory or long term oxygen therapy) 5) Neutrophil count < 2 x 10^9/l or White Blood Cell Count < 4.0 x 10^9/l 6) Current participation in another COVID-19 interventional trial 7) Known pregnancy or breastfeeding women 8) Women of child bearing potential who are unwilling to effective contraception (i.e. barrier, oral contraceptive pill, implanted contraception, or previous hysterectomy, bilateral oophorectomy) for the duration of the trial and the maximum period specified in Table 2. 9) Non-vasectomised men, sexually active with women of child bearing potential, who are not willing to practise effective contraception (i.e. condom with spermicide) for the duration of the trial and the maximum period specified in Table 2. 10) Known HIV or chronic Hepatitis B or C infection 11) Known contraindications to any of the Investigational Medicinal Products 12) Concurrent immunosuppression with biological agents or prednisone dose > 20mg 13) History of haematopoietic stem cell transplant or solid organ transplant 14) Any other indication or medical history, that in the opinion of the local investigator means the patient is unsuitable for trial participation 15) Patients with tuberculosis or other severe infections such as (non-COVID19) sepsis, abscesses, and opportunistic infections requiring treatment 16) Patients with moderate or severe heart failure (NYHA class III/IV) 17) Any other indication or medical history, that in the opinion of the local investigator means the patient is unsuitable for trial participation

1) Patient or legal representative refusal 2) Receiving palliative care with no active treatment 3) Known veno-occlusive disease 4) Chronic Obstructive Pulmonary Disease (known FEV1 < 50% predicted or ambulatory or long term oxygen therapy) 5) Neutrophil count < 2 x 10^9/l or White Blood Cell Count < 4.0 x 10^9/l 6) Current participation in another COVID-19 interventional trial 7) Known pregnancy or breastfeeding women 8) Women of child bearing potential who are unwilling to effective contraception (i.e. barrier, oral contraceptive pill, implanted contraception, or previous hysterectomy, bilateral oophorectomy) for the duration of the trial and the maximum period specified in Table 2. 9) Non-vasectomised men, sexually active with women of child bearing potential, who are not willing to practise effective contraception (i.e. condom with spermicide) for the duration of the trial and the maximum period specified in Table 2. 10) Known HIV or chronic Hepatitis B or C infection 11) Known contraindications to any of the Investigational Medicinal Products 12) Concurrent immunosuppression with biological agents or prednisone dose > 20mg 13) History of haematopoietic stem cell transplant or solid organ transplant 14) Any other indication or medical history, that in the opinion of the local investigator means the patient is unsuitable for trial participation 15) Patients with tuberculosis or other severe infections such as (non-COVID19) sepsis, abscesses, and opportunistic infections requiring treatment 16) Patients with moderate or severe heart failure (NYHA class III/IV) 17) Any other indication or medical history, that in the opinion of the local investigator means the patient is unsuitable for trial participation